-
Je něco špatně v tomto záznamu ?
The roles of p27(Kip1) and DNA damage signalling in the chemotherapy-induced delayed cell cycle checkpoint
M. Liontos, G. Velimezi, IS. Pateras, R. Angelopoulou, AG. Papavassiliou, J. Bartek, VG. Gorgoulis,
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, práce podpořená grantem
NLK
Free Medical Journals
od 2000
PubMed Central
od 2000
Europe PubMed Central
od 2000 do 2020
ProQuest Central
od 2000-07-01
Open Access Digital Library
od 2000-01-01
Open Access Digital Library
od 2006-01-01
Medline Complete (EBSCOhost)
od 2007-01-01
Health & Medicine (ProQuest)
od 2000-07-01
Wiley-Blackwell Open Access Titles
od 2000
ROAD: Directory of Open Access Scholarly Resources
od 2001
- MeSH
- ATM protein antagonisté a inhibitory MeSH
- buňky A549 MeSH
- chromony farmakologie MeSH
- doxorubicin farmakologie MeSH
- inhibitor p27 cyklin-dependentní kinasy fyziologie MeSH
- kofein farmakologie MeSH
- kontrolní body fáze G2 buněčného cyklu účinky léků MeSH
- lidé MeSH
- mitogenem aktivované proteinkinasy p38 metabolismus MeSH
- morfoliny farmakologie MeSH
- poškození DNA MeSH
- proteinkinasa aktivovaná DNA antagonisté a inhibitory MeSH
- proteiny asociované s kinázou S-fáze metabolismus MeSH
- protinádorové látky farmakologie MeSH
- pyrony farmakologie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
DNA lesions trigger the DNA damage response (DDR) machinery, which protects genomic integrity and sustains cellular survival. Increasing data underline the significance of the integrity of the DDR pathway in chemotherapy response. According to a recent work, persistent exposure of A549 lung carcinoma cells to doxorubicin induces an initial DDR-dependent checkpoint response, followed by a later DDR-independent, but p27(Kip1)-dependent one. Prompted by the above report and to better understand the involvement of the DDR signaling after chemotherapeutic stress, we examined the potential role of the canonical DDR pathway in A549 cells treated with doxorubicin. Exposure of A549 cells, prior to doxorubicin treatment, to ATM, ATR and DNA-PKcs inhibitors either alone or in various combinations, revealed that the earlier documented two-step response was DDR-dependent in both steps. Notably, inhibition of both ATM and ATR or selective inhibition of ATM or DNA-PKcs resulted in cell-cycle re-entry despite the increased levels of p27(Kip1) at all time points analyzed. We further investigated the regulation of p27(Kip1) protein levels in the particular setting. Our results showed that the protein status of p27(Kip1) is mainly determined by p38-MAPK, whereas the role of SKP2 is less significant in the doxoroubicin-treated A549 cells. Cumulatively, we provide evidence that the DNA damage signaling is responsible for the prolonged cell cycle arrest observed after persistent chemotherapy-induced genotoxic stress. In conclusion, precise identification of the molecular mechanisms that are activated during the chemotherapeutic cycles could potentially increase the sensitization to the therapy applied.
Centre for Genotoxic Stress Research Danish Cancer SocietyCopenhagen Denmark
Department of Biological Chemistry School of Medicine University of Athens Athens Greece
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc17014332
- 003
- CZ-PrNML
- 005
- 20170428113221.0
- 007
- ta
- 008
- 170413s2010 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1111/j.1582-4934.2010.01145.x $2 doi
- 035 __
- $a (PubMed)20716117
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Liontos, Michalis $u Molecular Carcinogenesis Group, Laboratory of Histology-Embryology, School of Medicine University of Athens, Greece.
- 245 14
- $a The roles of p27(Kip1) and DNA damage signalling in the chemotherapy-induced delayed cell cycle checkpoint / $c M. Liontos, G. Velimezi, IS. Pateras, R. Angelopoulou, AG. Papavassiliou, J. Bartek, VG. Gorgoulis,
- 520 9_
- $a DNA lesions trigger the DNA damage response (DDR) machinery, which protects genomic integrity and sustains cellular survival. Increasing data underline the significance of the integrity of the DDR pathway in chemotherapy response. According to a recent work, persistent exposure of A549 lung carcinoma cells to doxorubicin induces an initial DDR-dependent checkpoint response, followed by a later DDR-independent, but p27(Kip1)-dependent one. Prompted by the above report and to better understand the involvement of the DDR signaling after chemotherapeutic stress, we examined the potential role of the canonical DDR pathway in A549 cells treated with doxorubicin. Exposure of A549 cells, prior to doxorubicin treatment, to ATM, ATR and DNA-PKcs inhibitors either alone or in various combinations, revealed that the earlier documented two-step response was DDR-dependent in both steps. Notably, inhibition of both ATM and ATR or selective inhibition of ATM or DNA-PKcs resulted in cell-cycle re-entry despite the increased levels of p27(Kip1) at all time points analyzed. We further investigated the regulation of p27(Kip1) protein levels in the particular setting. Our results showed that the protein status of p27(Kip1) is mainly determined by p38-MAPK, whereas the role of SKP2 is less significant in the doxoroubicin-treated A549 cells. Cumulatively, we provide evidence that the DNA damage signaling is responsible for the prolonged cell cycle arrest observed after persistent chemotherapy-induced genotoxic stress. In conclusion, precise identification of the molecular mechanisms that are activated during the chemotherapeutic cycles could potentially increase the sensitization to the therapy applied.
- 650 _2
- $a buňky A549 $7 D000072283
- 650 _2
- $a protinádorové látky $x farmakologie $7 D000970
- 650 _2
- $a ATM protein $x antagonisté a inhibitory $7 D064007
- 650 _2
- $a kofein $x farmakologie $7 D002110
- 650 _2
- $a chromony $x farmakologie $7 D002867
- 650 _2
- $a inhibitor p27 cyklin-dependentní kinasy $x fyziologie $7 D050760
- 650 _2
- $a poškození DNA $7 D004249
- 650 _2
- $a proteinkinasa aktivovaná DNA $x antagonisté a inhibitory $7 D051747
- 650 _2
- $a doxorubicin $x farmakologie $7 D004317
- 650 _2
- $a kontrolní body fáze G2 buněčného cyklu $x účinky léků $7 D059565
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a morfoliny $x farmakologie $7 D009025
- 650 _2
- $a pyrony $x farmakologie $7 D011753
- 650 _2
- $a proteiny asociované s kinázou S-fáze $x metabolismus $7 D044786
- 650 _2
- $a mitogenem aktivované proteinkinasy p38 $x metabolismus $7 D048051
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Velimezi, Georgia $u Molecular Carcinogenesis Group, Laboratory of Histology-Embryology, School of Medicine University of Athens, Greece.
- 700 1_
- $a Pateras, Ioannis S $u Molecular Carcinogenesis Group, Laboratory of Histology-Embryology, School of Medicine University of Athens, Greece.
- 700 1_
- $a Angelopoulou, Roxani $u Molecular Carcinogenesis Group, Laboratory of Histology-Embryology, School of Medicine University of Athens, Greece. $7 gn_A_00006916
- 700 1_
- $a Papavassiliou, Athanasios G $u Department of Biological Chemistry, School of Medicine, University of Athens Athens, Greece.
- 700 1_
- $a Bartek, Jiri $u Centre for Genotoxic Stress Research, Danish Cancer SocietyCopenhagen, Denmark; Laboratory of genome integrity, Institute of Molecular and Translational Medicine, Palacky UniverzityOlomouc, Czech Republic.
- 700 1_
- $a Gorgoulis, Vassilis G $u Molecular Carcinogenesis Group, Laboratory of Histology-Embryology, School of Medicine University of Athens, Greece.
- 773 0_
- $w MED00006785 $t Journal of cellular and molecular medicine $x 1582-4934 $g Roč. 14, č. 9 (2010), s. 2264-7
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/20716117 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20170413 $b ABA008
- 991 __
- $a 20170428113543 $b ABA008
- 999 __
- $a ok $b bmc $g 1200797 $s 975110
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2010 $b 14 $c 9 $d 2264-7 $e 20101011 $i 1582-4934 $m Journal of cellular and molecular medicine $n J Cell Mol Med $x MED00006785
- LZP __
- $a Pubmed-20170413